In this work, a nanogenerator‐controlled drug delivery system (DDS) for use in cancer therapy is successfully established. A new magnet triboelectric nanogenerator (MTENG) is fabricated that can guarantee the contact and detach cycle between the two friction layers and effectively increase the TENG output, up to 70 V after implantation. Using a special structural design, without the commonly used spacer, this contacting‐mode MTENG can ensure a high and consistent electricity output after encapsulation and implantation. Doxorubicin‐(DOX‐) loaded red blood cells (RBCs) are employed as the anti‐tumor DDS in this study. After DOX loading, the RBC membranes are stable and the self‐release is very slow. However, upon electric stimulation from the MTENG, the release of DOX is remarkably increased, and falls back to normal again after the stimulation. Thus a controllable DDS is established. The MTENG‐controllable DDS achieves an outstanding killing of carcinomatous cells both in vitro and in vivo at a low DOX dosage. These results demonstrate a prominent therapeutic effect of the MTENG‐controlled DDS for cancer therapy, which is highly promising for application in the clinic.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: